Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease

Condition:   Acquired Immune Deficiency SyndromeInterventions:   Drug: Lopinavir 400 mg/ritonavir 100 mg;   Drug: EfavirenzSponsors:   Rush University Medical Center;   University of Chicago;   University of Illinois at Chicago;   Ruth M. Rothstein CORE Center;   Abbott;   Gilead SciencesTerminated - verified May 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials